Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer.

Journal of medical economics - 1 Jan 2017

Clopes Ana, Gasol Montse, Cajal Rosana, Segú Luis, Crespo Ricard, Mora Ramón, Simon Susana, Cordero Luis A, Calle Candela, Gilabert Antoni, Germà Josep R

Abstract excerpt

BACKGROUND: In 2011 the first payment-by-results (PbR) scheme in Catalonia was signed between the Catalan Institute of Oncology (ICO), the Catalan Health Service, and AstraZeneca (AZ) for the introduction of gefitinib in the treatment of advanced EGFR-mutation positive non-small-cell lung cancer. The PbR scheme includes two evaluation points: at week 8, responses, stabilization and progression were evaluated, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Costs

Share to Gefitinib

Share to Interviews as Topic

Share to Qualitative Research

Share to Quinazolines

Source

Identifiers

PMID: 27441909
DOI: 10.1080/13696998.2016.1215991

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer.PMID 27441909Read ↗

Cost-effectiveness analysis of first-line gefitinib plus anlotinib treatment for patients with stage IIIB-IV EGFR-mutated NSCLC in China.Semantic proximity Read ↗

Quantifying the Dual Value and Governance Risks of Early Access Programs in Oncology: A Single-Centre Analysis and National Policy FrameworkSemantic proximity Read ↗

Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study.Semantic proximity Read ↗

The costs and benefits of an early access scheme for oncology medicines in IrelandSemantic proximity Read ↗

Medical Insurance Payment Schemes and Patient Medical Expenses: A Cross- Sectional Study of Lung Cancer Patients in Urban ChinaSemantic proximity Read ↗

The Net Financial Benefits of Single Vendor Integrated CDMO and CRO Drug Development ServicesSemantic proximity Read ↗

Social return on investment economic evaluation of supportive care for lung cancer patients in acute care settings in AustraliaSemantic proximity Read ↗

Assessing the Value of Integrated Evidence Approaches in Drug DevelopmentSemantic proximity Read ↗

Socio-economic impact pathways of MedAustron: industrial spillovers and scientific knowledge production in a particle therapy research infrastructureSemantic proximity Read ↗

Protocol for the economic evaluation of LCS in Ireland: modelling costs, eligibility, and outcomesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.